Psoriasis

New England Journal of Medicine

Volumn 352, Issue 18, 2005, Pages 1899-1912

  Schön, Michael P ^a   Boehncke, W Henning ^b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; CALCIPOTRIOL; CELL ADHESION MOLECULE; CHEMOKINE; COLECALCIFEROL DERIVATIVE; CORTICOSTEROID; CYCLOSPORIN; CYTOKINE; EFALIZUMAB; ETANERCEPT; FUMARIC ACID DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; PSORALEN; RETINOID; TACALCITOL; TAZAROTENE; DERMATOLOGICAL AGENT;

CLINICAL FEATURE; GENETICS; HISTOPATHOLOGY; HUMAN; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; PHOTOTHERAPY; PREVALENCE; PRIORITY JOURNAL; PSORIASIS; PUVA; REVIEW; TOPICAL TREATMENT; IMMUNOLOGY; PATHOLOGY; PHYSIOLOGY; SKIN; T LYMPHOCYTE; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; CELL ADHESION MOLECULES; CHEMOKINES; CYTOKINES; DERMATOLOGIC AGENTS; HUMANS; PSORIASIS; SKIN; T-LYMPHOCYTES;

EID: 17944364473     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMra041320     Document Type: Review

References (102)

1. Lomholt G. Prevalence of skin diseases in a population; a census study from the Faroe Islands. Dan Med Bull 1964;11:1-7.
2. Farber EM, Nall ML. Epidemiology: natural history and genetics. In: Roenigk HH, Maibach HI, eds. Psoriasis. New York: Marcel Dekker, 1998:107-58.
3. Kenney JA. Psoriasis in the American black. In: Farber EM, Cox AJ, eds. Psoriasis: proceedings of the International Symposium, Stanford University. Stanford, Calif: Stanford University Press, 1971:49-52.
4. Christophers E. Psoriasis-epidemiology and clinical spectrum. Clin Exp Dermatol 2001;26:314-20.
5. Henseler T, Christophers E. Psoriasis of early and late onset characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 1985;13:450-6.
6. Watson W, Cann HM, Farber EM, Nall ML. The genetics of psoriasis. Arch Dermatol 1972;105:197-207.
7. Farber EM, Nall ML, Watson W. Natural history of psoriasis in 61 twin pairs. Arch Dermatol 1974;109:207-11.
8. Brandrup F, Holm N, Grunnet N, Henningsen K, Hansen HE. Psoriasis in monozygotic twins: variations in expression in individuals with identical genetic constitution. Acta Derm Venereol 1982;62:229-36.
9. Morris A, Rogers M, Fischer G, Williams K. Childhood psoriasis: a clinical review of 1262 cases. Pediatr Dermatol 2001; 18:188-98.
10. Altmüller J, Palmer LJ, Fischer G, Scherb H, Wjst M. Genomewide scans of complex human diseases: true linkage is hard to find. Am J Hum Genet 2001;69:936-50. [Erratum, Am J Hum Genet 2001;69: 1413.]
11. Altmüller J, Palmer LJ, Fischer G, Scherb H, Wjst M. Genomewide scans of complex human diseases: true linkage is hard to find. Am J Hum Genet 2001;69:936-50. [Erratum, Am J Hum Genet 2001;69: 1413.]
12. Davidson A, Diamond B. Autoimmune diseases. N Engl J Med 2001;345:340-50.
13. Trembath RC, Clough RL, Rosbotham JL, et al. Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genet 1997;6:813-20.
14. Burden AD, Javed S, Bailey M, Hodgins M, Connor M, Tillman D. Genetics of psoriasis: paternal inheritance and a locus on chromosome 6p. J Invest Dermatol 1998; 110:958-60.
15. Mallon E, Bunce M, Wojnarowska F, Welsh K. HLA-CW*0602 is a susceptibility factor in type I psoriasis, and evidence Ala-73 is increased in male type I psoriatics. J Invest Dermatol 1997;109:183-6.
16. Asumalahti K, Veal C, Laitinen T, et al. Coding haplotype analysis supports HCR as the putative susceptibility gene for psoriasis at the MHC PSORS1 locus. Hum Mol Genet 2002;11:589-97.
17. Allen MH, Veal C, Faassen A, et al. A non-HLA gene within the MHC in psoriasis. Lancet 1999;353:1589-90.
18. Tomfohrde J, Silverman A, Barnes R, et al. Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q. Science 1994;264:1141-5.
19. Matthews D, Fry L, Powles A, et al. Evidence that a locus for familial psoriasis maps to chromosome 4q. Nat Genet 1996; 14:231-3.
20. Capon F, Novelli G, Semprini S, et al. Searching for psoriasis susceptibility genes in Italy: genome scan and evidence for a new locus on chromosome 1. J Invest Dermatol 1999;112:32-5.
21. Enlund F, Samuelsson L, Enerback C, et al. Psoriasis susceptibility locus in chromosome region 3q21 identified in patients from southwest Sweden. Eur J Hum Genet 1999;7:783-90.
22. Lee YA, Ruschendorf F, Windemuth C, et al. Genomewide scan in German families reveals evidence for a novel psoriasis-susceptibility locus on chromosome 19p13. Am J Hum Genet 2000;67:1020-4.
23. Veal CD, Clough RL, Barber RC, et al. Identification of a novel psoriasis susceptibility locus at 1p and evidence of epistasis between PSORS1 and candidate loci. J Med Genet 2001;38:7-13.
24. Helms C, Cao L, Krueger JG, et al. A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis. Nat Genet 2003;35:349-56.
25. Owen CM, Chalmers RJ, O'Sullivan T, Griffiths CE. Antistreptococcal interventions for guttate and chronic plaque psoriasis. Cochrane Database Syst Rev 2000;2: CD001976.
26. Lavaroni G, Kokelj F, Pauluzzi P, Trevisan G. The nails in psoriatic arthritis. Acta Derm Venereol Suppl (Stockh) 1994;186:113.
27. Zachariae H. Prevalence of joint disease in patients with psoriasis: implications for therapy. Am J Clin Dermatol 2003;4:441-7.
28. Eyre RW, Krueger GG. Response to injury of skin involved and uninvolved with psoriasis and its relation to disease activity: Koebner and 'reverse' Koebner. Br J Dermatol 1982;106:153-9.
29. Tsankov N, Angelova I, Kazandjieva J. Drug-induced psoriasis: recognition and management. Am J Clin Dermatol 2000;1: 159-65.
30. Mallon E. Retroviruses and psoriasis. Curr Opin Infect Dis 2000;13:103-7.
31. Christophers E. The immunopathology of psoriasis. Int Arch Allergy Immunol 1996; 110:199-206.
32. Detmar M, Brown LF, Claffey KP, et al. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 1994; 180:1141-6.
33. Schlaak JF, Buslau M, Jochum W, et al. T cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol 1994; 102:145-9.
34. Pauls K, Schön M, Kubitza RC, et al. Role of integrin αE(CD103)β7 for tissue-specific epidermal localization of CD8+ T lymphocytes. J Invest Dermatol 2001;117: 569-75.
35. Ovigne J-M, Baker BS, Davison SC, Powles AV, Fry L. Epidermal CD8+ T cells reactive with group A streptococcal antigens in chronic plaque psoriasis. Exp Dermatol 2002;11:357-64.
36. Pinkus H, Mehregan AH. The primary histologic lesion of seborrheic dermatitis and psoriasis. J Invest Dermatol 1966;46: 109-16.
37. Rothe MJ, Nowak M, Kerdel FA. The mast cell in health and disease. J Am Acad Dermatol 1990;23:615-24.
38. Grakoui A, Bromley SK, Sumen C, et al. The immunological synapse: a molecular machine controlling T cell activation. Science 1999;285:221-7.
39. Mueller W, Herrmann B. Cyclosporin A for psoriasis. N Engl J Med 1979;301:555.
40. Gottlieb JL, Gilleaudeau P, Johnson R, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1995;1:442-7.
41. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001;345:248-55.
42. Kupper TS. Immunologic targets in psoriasis. N Engl J Med 2003;349:1987-90.
43. Lebwohl M, Tyring SK, Hamilton TK, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003;349:2004-13.
44. Prinz J, Braun-Falco O, Meurer M, et al. Chimaeric CD4 monoclonal antibody in treatment of generalized pustular psoriasis. Lancet 1991;338:320-1.
45. Nicolas JF, Chamchick N, Thivolet J, Wijdenes J, Morel P, Revillard JP. CD4 antibody treatment of severe psoriasis. Lancet 1991;338:321.
46. Eedy DJ, Burrows D, Bridges JM, Jones FGC. Clearance of severe psoriasis after allogenic bone marrow transplantation. BMJ 1990;300:908.
47. Gardembas-Pain M, Ifrah N, Foussard C, Boasson M, Saint Andre JP, Verret JL. Psoriasis after allogeneic bone marrow transplantation. Arch Dermatol 1990;126:1523.
48. Bour H, Puisieux I, Kourilsky P, Favrot M, Musette P, Nicolas JF. T-cell repertoire analysis in chronic plaque psoriasis suggests an antigen-specific immune response. Hum Immunol 1999;60:665-76.
49. Vekony MA, Holder JE, Lee AJ, Horrocks C, Eperon IC, Camp RD. Selective amplifications of T-cell receptor variable region species is demonstrable butnot essential in early lesions of psoriasis vulgaris: analysis by anchored polymerase chain reaction and hypervariable region size spectratyping. J Invest Dermatol 1997;109:5-13.
50. Boehncke W-H. Psoriasis and bacterial superantigens - formal or causal correlation? Trends Microbiol 1996;4:485-9.
51. Gudmundsdottir AS, Sigmundsdottir H, Sigurgeirsson B, Good MF, Valdimarsson H, Jonsdottir I. Is an epitope on keratin 17 a major target for autoreactive T lymphocytes in psoriasis? Clin Exp Immunol 1999; 117:580-6.
52. + T-cells. Nat Med 1997;3:183-8.
53. Breban M, Fernandez-Sueiro JL, Richardson JA, et al. T cells, butnotthymic exposure to HLA-B27, are required for the inflammatory disease of HLA-B27 transgenic rats. J Immunol 1996;156:794-803.
54. Boehncke W-H, Dressel D, Zollner TM, Kaufmann R. Pulling the trigger on psoriasis. Nature 1996;379:777.
55. Wrone-Smith T, Nickoloff BJ. Dermal injection of immunocytes induces psoriasis. J Clin Invest 1996;98:1878-87.
56. Schön MP. Animal models of psoriasis - what can we learn from them? J Invest Dermatol 1999;112:405-10.
57. Boyman O, Hefti HP, Conrad C, Nickoloff BJ, Suter M, Nestle FO. Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha. J Exp Med 2004;199:731-6.
58. Nickoloff BJ. The cytokine network of psoriasis. Arch Dermatol 1991;127:871-84.
59. Schön MP, Ruzicka T. Psoriasis: the plot thickens . . . . Nat Immunol 2001;2:91.
60. Murphy JE, Robert C, Kupper TS. Interleukin-1 and cutaneous inflammation: a crucial link between innate and acquired immunity. J Invest Dermatol 2000;114:602-8.
61. Barker JNWN, Karabin GD, Stoof TJ, Sarma VJ, Dixit VM, Nickoloff BJ. Detection of interferon-gamma mRNA in psoriatic epidermis by polymerase chain reaction. J Dermatol Sci 1991;2:106-11.
62. Neuner P, Urbanski A, Trautinger F, et al. Increased IL-6 production by monocytes and keratinocytes in patients with psoriasis. J Invest Dermatol 1991;97:27-33.
63. Elder JT, Fisher GJ, Lindquist PB, et al. Overexpression of transforming growth factor α in psoriatic epidermis. Science 1989; 243:811-4.
64. Griffiths CEM, Voorhees JJ, Nickoloff BJ. Characterization of intercellular adhesion molecule-1 and HLA-DR expression in normal and inflamed skin: modulation by recombinant gamma interferon and tumor necrosis factor. J Am Acad Dermatol 1989; 20:617-29.
65. Barker JNWN, Sarma V, Mitra RS, Dixit VM, Nickoloff BJ. Marked synergism between tumor necrosis factor-alpha and interferon-gamma in regulation of keratinocyte-derived adhesion molecules and chemotactic factors. J Clin Invest 1990;85:605-8.
66. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003;349: 2014-22.
67. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001;357:1842-7.
68. Kuroda K, Sapadin A, Shoji T, Pleischmajer R, Lebwohl M. Altered expression of angiopoietins and Tie2 endothelium receptor in psoriasis. J Invest Dermatol 2001;116: 713-20.
69. Michel G, Mirmohammadsadegh A, Olasz E, et al. Demonstration and functional analysis of IL-10 receptors in human epidermal cells: decreased expression in psoriatic skin, down-modulation by IL-8, and upregulation by an antipsoriatic glucocorticosteroid in normal cultured keratinocytes. J Immunol 1997;159:6291-7.
70. Asadullah K, Sterry W, Stephanek K, et al. IL-10 is a key cytokine in psoriasis: proof of principle by IL-10 therapy: a new therapeutic approach. J Clin Invest 1998;101: 783-94.
71. Ghoreschi K, Thomas P, Breit S, et al. Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat Med 2003;9:40-6.
72. Homey B, Alenius H, Müller A, et al. CCL27-CCR10 interactions regulate T cell-mediated skin inflammation. Nat Med 2002;8:157-65.
73. Campbell JJ, Haraldsen G, Pan J, et al. The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells. Nature 1999;400:776-80.
74. Goebeler M, Toksoy A, Spandau U, Engelhardt E, Bröcker E-B, Gillitzer R. The C-X-C chemokine Mig is highly expressed in the papillae of psoriatic lesions. J Pathol 1998;184:89-95.
75. Homey B. Chemokines and chemokine receptors as targets in the therapy of psoriasis. Curr Drug Targets Inflamm Allergy 2004;3:169-74.
76. Steinhoff M, Ständer S, Seeliger S, Ansel JC, Schmelz M, Luger TA. Modern aspects of cutaneous neurogenic inflammation. Arch Dermatol 2003;139:1479-88.
77. Raychaudhuri SP, Raychaudhuri SK. Role of NGF and neurogenic inflammation in the pathogenesis of psoriasis. Prog Brain Res 2004;146:433-7.
78. Robert C, Kupper TS. Inflammatory skin diseases, T cells, and immune surveillance. N Engl J Med 1999;341:1817-28.
79. Schön MP, Zollner TM, Boehncke WH. The molecular basis of lymphocyte recruitment to the skin: clues for pathogenesis and selective therapies of inflammatory disorders. J Invest Dermatol 2003;121:951-62.
80. Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science 1996;272:60-6.
81. von Andrian UH, Mackay CR. T-cell function and migration: two sides of the same coin. N Engl J Med 2000;343:1020-34.
82. Ley K. Functions of selectins. Results Probl Cell Differ 2001;33:177-200.
83. Bhushan M, Bleiker TO, Ballsdon AE, et al. Anti-E-selectin is ineffective in the treatment of psoriasis: a randomized trial. Br J Dermatol 2002;146:824-31.
84. Schön MP, Krahn T, Schön M, et al. Efomycine M, a new specific inhibitor of selectin, impairs leukocyte adhesion and alleviates cutaneous inflammation. Nat Med 2002; 8:366-72. [Erratum, Nat Med 2002;8:639.]
85. Schön MP, Krahn T, Schön M, et al. Efomycine M, a new specific inhibitor of selectin, impairs leukocyte adhesion and alleviates cutaneous inflammation. Nat Med 2002; 8:366-72. [Erratum, Nat Med 2002;8:639.]
86. Fuhlbrigge RC, Kieffer JD, Armerding D, Kupper TS. Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells. Nature 1997;389:978-81.
87. Picker LJ, Michie SA, Rott LS, Butcher EC. A unique phenotype of skin-associated lymphocytes in humans: preferential expression of the HECA-425 epitope by benign and malignant T cells at cutaneous sites. Am J Pathol 1990;136:1053-68.
88. Dustin ML, Singer KH, Tuck DT, Springer TA. Adhesion of T lymphoblasts to epidermal keratinocytes is regulated by interferon gamma and is mediated by intercellular adhesion molecule 1 (ICAM-1). J Exp Med 1988;167:1323-40.
89. Cepek KL, Shaw SK, Parker CM, et al. Adhesion between epithelial cells and T lymphocytes mediated by E-cadherin and the alpha E beta 7 integrin. Nature 1994;372: 190-3.
90. Rottman JB, Smith TL, Ganley KG, Kikuchi T, Krueger JG. Potential role of the chemokine receptors CXCR3, CCR4, and the integrin alphaEbeta7 in the pathogenesis of psoriasis vulgaris. Lab Invest 2001;81: 335-47.
91. Schon MP, Drewniok C, Boehncke W-H. Targeting selectin functions in the therapy of psoriasis. Curr Drug Targets Inflamm Allergy 2004;3:163-8.
92. Boehncke W-H, Schön MP. Interfering with leukocyte rolling-a promising therapeutic approach in inflammatory skin disorders? Trends Pharmacol Sci 2003;24:49-52.
93. Heydendael VMR, Spuls PI, Opmeer BC, et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003;349:658-65.
94. Granstein RP. New treatments for psoriasis. N Engl J Med 2001;345:284-7.
95. Mendonca CO, Burden AD. Current concepts in psoriasis and its treatment Pharmacol Ther 2003;99:133-47.
96. Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 2004;113:1664-75.
97. Boehncke WH. Immunomodulatory drugs for psoriasis. BMJ 2003;327:634-5.
98. van de Kerkhof PCM, de Hoop D, de Korte J, Cobelens SA, Kuipers MV. Patient compliance and disease management in the treatment of psoriasis in the Netherlands. Dermatology 2000;200:292-8.
99. Krueger GG, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001;137: 280-4.
100. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999;41: 401-7.
101. Gottlieb AB, Lebwohl M, Shirin S, et al. Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multi-center, multiple-dose, placebo-controlled study. J Am Acad Dermatol 2000;43:595-604.
102. Asadullah K, Volk HD, Sterry W. Novel immunotherapies for psoriasis. Trends Immunol 2002;23:47-53.